Palisade Bio, Inc. announced on March 14, 2025, that it has commenced dosing of the first ulcerative colitis (UC) patient in the final cohort of its Phase 1a/b study of PALI-2108. This marks a significant transition in the clinical trial, moving from healthy volunteers to patients with the target disease.
The company also reported the completion of all five previous Phase 1a single ascending dose (SAD) cohorts and the first three of four multiple ascending dose (MAD) cohorts. Importantly, no serious adverse events (SAEs) or treatment-emergent adverse events (TEAEs) related to laboratory values or EKGs have been observed to date.
Preliminary results from the SAD and MAD cohorts align with management’s expectations, underscoring the safety and tolerability of PALI-2108 at therapeutic dose levels. Palisade Bio remains on track to report topline data from the study in the first half of 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.